Interleukin-18 inhibits osteolytic bone metastasis by human lung cancer cells possibly through suppression of osteoclastic bone-resorption in nude mice

Journal of Immunotherapy

Volumn 25, Issue SUPPL. 1, 2002, Pages

  Iwasaki, Teruo ^a   Yamashita, Kunihiro ^a   Tsujimura, Tohru ^a   Kashiwamura, Shin ichiro ^a   Tsutsui, Hiroko ^a   Kaisho, Tsuneyasu ^a   Sugihara, Ayako ^a   Yamada, Naoko ^a   Mukai, Mutsuko ^a   Yoneda, Toshiyuki ^a   Okamura, Haruki ^a   Akedo, Hitoshi ^a   Terada, Nobuyuki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Experimental therapy; Interleukin 18; Lung cancer; Nude mouse model; Osteolytic bone metastasis

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; KI 67 ANTIGEN; RECOMBINANT INTERLEUKIN 18; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; BONE METASTASIS; CANCER CELL CULTURE; CANCER GROWTH; CELL LABELING; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; LUNG CANCER; MALE; MITOSIS INDEX; NATURAL KILLER CELL; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPLEEN CELL; TREATMENT OUTCOME;

ANIMALS; BONE NEOPLASMS; BONE RESORPTION; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; INTERFERON TYPE II; INTERLEUKIN-18; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED A; NEOPLASM TRANSPLANTATION; OSTEOLYSIS; PROBABILITY; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TUMOR CELLS, CULTURED;

EID: 18344386201     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200203001-00008     Document Type: Conference Paper

References (38)

1. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families
2. Cell biology of the osteoclast
3. Breast cancer cells interact with osteoblasts to support osteoclast formation
4. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity
5. Breast cancer cell line MDA-231 stimulates osteoclastogenesis and bone resorption in human osteoclasts
6. Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation
7. Cancer and bone
8. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma
9. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice
10. Cloning of a new cytokine that induces IFN-γ production by T cells
11. Cloning of the cDNA for human IFN-γ-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein
12. Interleukin-18: A novel cytokine that augments both innate and acquired immunity
13. Interleukin-18: Biological properties and clinical implications
14. Interleukin 18, interferon γ inducing factor, a novel player in tumor immunotherapy?
15. Interleukin-18 (interferon-γ-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-γ to inhibit osteoclast formation
16. Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells
17. Neutralizing antibodies to human interleukin 6 reverse hypercalcemia associated with a human squamous carcinoma
18. G-nitro-L-arginine methyl ester inhibits bone metastasis after modified intracardiac injection of human breast cancer cells in a nude mouse model
19. Expression and prognostic significance in lung cancer of human tumor-associated antigen RCAS1
20. IL-18 up-regulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor
21. IFN-γ-dependent and -independent mechanisms in adverse effects caused by concomitant administration of IL-18 and IL-12
22. IL-18 and IL-12 induce intestinal inflammation and fatty liver in mice in an IFN-γ dependent manner
23. Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18
24. Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor
25. IFN-γ-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones
26. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma
27. In vivo antitumor effects of murine interferon-γ-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites
28. Interferon-γ-inducing factor elicits antitumor immunity in association with interferon-γ production
29. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively
30. Potent antitumor effects mediated by local expression of the mature form of the interferon-γ inducing factor, interleukin-18 (IL-18)
31. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells
32. Antitumor activity of interleukin-18 on mouse glioma cells
33. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis
34. Interleukin-18 acts as an angiogenesis and tumor suppressor
35. gp130 cytokine family and bone cells
36. 3 or parathyroid hormone
37. IL-18-deficient mice are resistant to endotoxin-induced liver injury but highly susceptible to endotoxin shock
38. Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells